Sexually transmitted diseases (STDs), or sexually transmitted infections (STIs), are an important global health priority because of their devastating impact on women and infants and their inter-relationships with HIV/AIDS biologically and epidemiologically. The ultimate objective of NIAID-supported research is to develop effective prevention and treatment approaches to control STDs.
NIAID is always accepting researcher-initiated applications. Connect with NIAID program officers about potential funding for STD/STI research.
For contact information, search the NIH Enterprise Directory.
- Dr. Eleanore Chuang, STI Clinical Research Program Officer
- Dr. Thomas Hiltke, STIs Section Chief, STI Vaccines and Therapeutics Program Officer
- Kimberly Murphy, Product Development Project Manager for STIs
- Dr. Leah Vincent, STIs Basic Research Program Officer
- Peter Wolff, Clinical Trials Specialist
Connect With Other Researchers
Researchers at NIAID
Much of the STD research ongoing at NIAID takes place in these laboratories:
Laboratory of Immunoregulation
- Thomas C. Quinn, M.D., M.Sc., International HIV/STD Section
- Steven J. Reynolds, M.D., M.P.H., International HIV/STD Section
Laboratory of Infectious Diseases
- Jeffrey Cohen, M.D., Medical Virology Section
Laboratory of Viral Diseases
- Thomas M. Kristie, Ph.D., Molecular Genetics Section
- Alison McBride, Ph.D., DNA Tumor Virus Section
Laboratory of Bacteriology
- David (Ted) Hackstadt, Ph.D., Host-Parasite Interactions Section
Laboratory of Clinical Immunology and Microbiology
- Harlan D. Caldwell, Ph.D., Chlamydial Diseases Section
Resources for Researchers
You may request services if you are an investigator in academia, a not-for-profit organization, industry, or government in the United States or worldwide. You need not be a grantee of NIAID or another National Institutes of Health Institute or Center. Look to each resource for further eligibility information.
Current Challenges in Evaluating Antimicrobials for Urogenital Gonorrhea
Experts Collaborate to Design Thorough and Effective Future Trials
February 5-6, 2019